RT Journal Article
T1 HisAK70: progress towards a vaccine against different forms of leishmaniosis
A1 Carrión Herrero, Francisco Javier
A1 Domínguez Bernal, Gustavo Ramón
A1 Horcajo Iglesias, María Del Pilar
A1 Orden Gutiérrez, José Antonio
A1 Ruiz Santa Quiteria Serrano De La Cruz, José Antonio
A1 Fuente López, Ricardo De La
A1 Mas Zubiri, Alicia
A1 Martínez Rodrigo, Abel
A1 Ordóñez Gutiérrez, Lara
AB BackgroundLeishmania major and Leishmania infantum are among the main species that are responsible for cutaneous leishmaniosis (CL) and visceral leishmaniosis (VL), respectively. The leishmanioses represent the second-largest parasitic killer in the world after malaria. Recently, we succeeded in generating a plasmid DNA (pCMV-HISA70m2A) and demonstrated that immunized mice were protected against L. major challenge. The efficacy of the DNA-vaccine was further enhanced by the inclusion of KMP-11 antigen into the antibiotic-free plasmid pVAX1-asd.MethodsHere, we describe the use of a HisAK70 DNA-vaccine encoding seven Leishmania genes (H2A, H2B, H3, H4, A2, KMP11 and HSP70) for vaccination of mice to assess the induction of a resistant phenotype against VL and CL.ResultsHisAK70 was successful in vaccinated mice, resulting in a high amount of efficient sterile hepatic granulomas associated with a hepatic parasite burden fully resolved in the VL model; and resulting in 100 % inhibition of parasite visceralization in the CL model.ConclusionsThe results suggest that immunization with the HisAK70 DNA-vaccine may provide a rapid, suitable, and efficient vaccination strategy to confer cross-protective immunity against VL and CL.
SN 1756-3305
YR 2015
FD 2015-12
LK https://hdl.handle.net/20.500.14352/92575
UL https://hdl.handle.net/20.500.14352/92575
LA eng
DS Docta Complutense
RD 7 oct 2024